Phase I/IIa Trial of Folate Binding Protein (FBP) Peptide (E39) Vaccine in Ovarian and Endometrial Cancer Patients
Phase of Trial: Phase I/II
Latest Information Update: 17 Mar 2017
At a glance
- Drugs GALE 301 (Primary) ; GALE 302 (Primary)
- Indications Endometrial cancer; Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Adverse reactions; Proof of concept
- 17 Mar 2017 According to a Galena Biopharma media release, data from this study was given during an oral presentation at the Annual Meeting on Women's Cancer 2017 hosted by the Society of Gynecologic Oncology.
- 17 Mar 2017 Final analysis results published in a Galena Biopharma media release.
- 09 Mar 2017 Status changed from active, no longer recruiting to completed, as reported in a Galena Biopharma media release.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History